



**National Marrow  
Donor Program®**

Entrusted to operate the  
C.W. Bill Young  
Cell Transplantation Program

**National Coordinating Center**  
3001 Broadway St. N.E.  
Suite 100  
Minneapolis, MN 55413-1753

Toll Free: 1 (800) 526-7809  
Phone: (612) 627-5800  
marrow.org

February 10, 2009

Cdr. Elizabeth Montcalm-Smith  
Office of Naval Research (ONR 342)  
875 N. Randolph St.  
Arlington, VA 22203-1995

**Subject: Quarterly Performance/Technical Report of the National Marrow Donor Program®**

**Reference:** Grant Award #N00014-06-1-1207 between the Office of Naval Research and the National Marrow Donor Program

Dear Cdr. Montcalm-Smith:

Enclosed is subject document which provides the performance activity for each statement of work task item of the above reference for the period of September 1, 2008 to December 31, 2008.

Should you have any questions as to the scientific content of the tasks and the performance activity of this progress report, you may contact our Chief Medical Officer – Dennis L Confer, MD directly at 612-362-3425.

With this submittal of the quarterly progress report, the National Marrow Donor Program has satisfied the reporting requirements of the above reference for quarterly documentation. Other such quarterly documentation has been previously submitted under separate cover.

Please direct any questions pertaining to the cooperative agreement to my attention (612-362-3403 or at [cabler@nmdp.org](mailto:cabler@nmdp.org)).

Sincerely,

A handwritten signature in blue ink that reads "Carla Abler-Erickson".

Carla Abler-Erickson, MA  
Sr. Contracts Representative

Enclosure: Quarterly Report with SF298

C: D. Ivery – ACO (ONR-Chicago), letter and enclosure  
Dr. Robert J. Hartzman, CAPT, MC, USN (Ret): letter and enclosure  
Jennifer Ng, PhD – C.W. Bill Young Marrow Donor Recruitment and Research Program, letter and enclosure  
J. Rike - DTIC (Ste 0944): letter and enclosure  
NRL (Code 5227): letter and enclosure  
Dennis Confer, MD, Chief Medical Officer, NMDP, letter only  
Michelle Setterholm, NMDP letter only

<b>REPORT DOCUMENTATION PAGE</b>				<b>Form Approved OMB No. 0704-0188</b>	
<small>Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Service, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188) Washington, DC 20503.</small>					
<b>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.</b>					
<b>1. REPORT DATE</b> (DD-MM-YYYY) 10-02-2009		<b>2. REPORT TYPE</b> Quarterly		<b>3. DATES COVERED</b> (From - To) Oct – Dec 2008	
<b>4. TITLE AND SUBTITLE</b> Quarterly Performance / Technical Report				<b>5a. CONTRACT NUMBER</b> N/A	
				<b>5b. GRANT NUMBER</b> N00014-08-1-1207	
				<b>5c. PROGRAM ELEMENT NUMBER</b> N/A	
<b>6. AUTHOR(S)</b> Setterholm, Michelle				<b>5d. PROJECT NUMBER</b> N/A	
				<b>5e. TASK NUMBER</b> Project 1, 2, 3, 4	
				<b>5f. WORK UNIT NUMBER</b> N/A	
<b>7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)</b> National Marrow Donor Program 3001 Broadway St., N.E., Ste. 500 Minneapolis, MN 55413				<b>8. PERFORMING ORGANIZATION REPORT NUMBER</b> N/A	
<b>9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)</b> Office of Naval Research 875 N. Randolph St. Arlington, VA 22203				<b>10. SPONSOR/MONITOR'S ACRONYM(S)</b> ONR	
				<b>11. SPONSORING/MONITORING AGENCY REPORT NUMBER</b> N/A	
<b>12. DISTRIBUTION AVAILABILITY STATEMENT</b> Approved for public release; distribution is unlimited					
<b>13. SUPPLEMENTARY NOTES</b> N/A					
<b>14. ABSTRACT</b> <u>1. Contingency Preparedness:</u> Collect information from transplant centers, build awareness of the Transplant Center Contingency Planning Committee and educate the transplant community about the critical importance of establishing a nationwide contingency response plan.  <u>2. Rapid Identification of Matched Donors :</u> Increase operational efficiencies that accelerate the search process and increase patient access are key to preparedness in a contingency event.  <u>3. Immunogenetic Studies:</u> Increase understanding of the immunologic factors important in HSC transplantation.  <u>4. Clinical Research in Transplantation:</u> Create a platform that facilitates multicenter collaboration and data management.					
<b>15. SUBJECT TERMS</b> Research in HLA Typing, Hematopoietic Stem Cell Transplantation and Clinical Studies to Improve Outcomes					
<b>16. SECURITY CLASSIFICATION OF:</b>			<b>17. LIMITATION OF ABSTRACT</b> Same as Report	<b>18. NUMBER OF PAGES</b> 13	<b>19a. NAME OF RESPONSIBLE PERSON</b> Dennis L. Confer, MD – Chief Medical Office
<b>a. REPORT</b> U	<b>b. ABSTRACT</b> U	<b>c. THIS PAGE</b> U			<b>19b. TELEPHONE NUMBER (Include area code)</b> 612.362.3425

Grant Award N00014-08-1-1207

QUARTERLY  
PERFORMANCE / TECHNICAL REPORT  
FOR  
SEPTEMBER 01, 2008 to DECEMBER 31, 2008

Office of Naval Research

And

The National Marrow Donor Program  
3001 Broadway Street N.E.  
Minneapolis, MN 55413  
1-800-526-7809

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****September 01, 2008 through December 31, 2008**

<b>TABLE OF CONTENTS</b>			
<b>TASK</b>	<b>DESCRIPTION</b>	<b>STATUS</b>	<b>PAGE</b>
<b>IIA</b>	<b>Contingency Preparedness</b>		
<b>IIA.1</b>	<b>Objective 1 – Care Plans by Transplant Physicians</b>		
IIA.1.1	Task 1 – Secure Interest of Transplant Physicians	Open	4
IIA.1.2	Task 2 – GCSF in Radiation Exposure	No Activity	4
IIA.1.3	Task 3 – Patient Assessment Guidelines	No Activity	4
IIA.1.4	Task 4 – National Data Collection and Management Model	No Activity	5
<b>IIA.2</b>	<b>Objective 2 – Coordination of Care of Casualties</b>		
IIA.2.1	Task 1 – Contingency Response Network	Open	5
IIA.2.2	Task 2 – Standard Operating Procedures	No Activity	6
<b>IIA.3</b>	<b>Objective 3 – Information Technology Infrastructure</b>		
IIA.3.1	Task 1 – Disaster Recovery	No Activity	6
IIA.3.2	Task 2 – Critical Facility and Staff Related Functions	Open	6
<b>IIB</b>	<b>Rapid Identification of Matched Donors</b>		
<b>IIB.1</b>	<b>Objective 1 – Resolution of Speeds Donor Selection</b>		
IIB.1.1	Task 1 – Increase Registry Diversity	No Activity	7
IIB.1.2	Task 2 – Evaluate HLA-DRB1 High Resolution Typing	Closed	7
IIB.1.3	Task 3 – Evaluate HLA-C Typing of Donors	Closed	7
IIB.1.4	Task 4 – Evaluate Buccal Swabs	No Activity	7
IIB.1.5	Task 5 – Enhancing HLA Data for Selected Donors	No Activity	7
IIB.1.6	Task 6 – Maintain a Quality Control Program	No Activity	7
<b>IIB.2</b>	<b>Objective 2 – Improve HLA Quality &amp; Resolution</b>		
IIB.2.1	Task 1 – Collection of Primary Data	No Activity	7
IIB.2.2	Task 2 – Validation of Logic of Primary Data	Closed	8
IIB.2.3	Task 3 – Reinterpretation of Primary Data	Closed	8
IIB.2.4	Task 4 – Genotype Lists & Matching Algorithm	No Activity	8
<b>IIB.3</b>	<b>Objective 3 – Algorithm to Predict Best Donor</b>		
IIB.3.1	Task 1 – Incorporate Frequencies into Matching Algorithm	No Activity	8
IIB.3.2	Task 2 – Enhancement of EM Algorithm	No Activity	8
IIB.3.3	Task 3 – Optimal Registry Size Analysis	No Activity	8
IIB.3.4	Task 4 – Target Underrepresented Phenotypes	No Activity	8
IIB.3.5	Task 5 – Bioinformatics Web Site	Closed	8

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****September 01, 2008 through December 31, 2008**

IIB.3.6	Task 6 – Utilize Search Strategy Advisors to Improve Algorithm	Closed	8
<b>IIB.4</b>	<b>Objective 4 – Reduction of Donor Matching Time</b>		
IIB.4.1	Task 1 – Expand Network Communications	No Activity	9
IIB.4.2	Task 2 – Central Contingency Management	No Activity	9
IIB.4.3	Task 3 – Benchmarking Analysis	Closed	9
IIB.4.4	Task 4 – Expand Capabilities of Collection and Apheresis Centers	No Activity	9
<b>IIC.</b>	<b>Immunogenetic Studies</b>		
<b>IIC.1</b>	<b>Objective 1 – Influence of HLA Mismatches</b>		
IIC.1.1	Task 1 – Donor Recipient Pair Project	No Activity	9
<b>IIC.2</b>	<b>Objective 1 – Role of Other Loci and GVHD</b>		
IIC.2.1	Task 1 – Analysis of Non-HLA Loci	No Activity	9
IIC.2.2	Task 2 – Related Pairs Research Repository	No Activity	9
<b>IID</b>	<b>Clinical Research in Transplantation</b>		
<b>IID.1</b>	<b>Objective 1 – Clinical Research Improves Outcomes</b>		
IID.1.1	Task 1 – Observational Research, Clinical Trials and NIH Transplant Center	No Activity	10
IID 1.2	Task 2 – Research with NMDP Donors	No Activity	10
IID.1.3	Task 3 – Expand Immunobiology Research	No Activity	10
	Acronym List		11

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****September 01, 2008 through December 31, 2008****IIA. Contingency Preparedness – Objective 1:** Recovery of casualties with significant myelosuppression following radiation or chemical exposure is optimal when care plans are designed and implemented by transplant physicians

<b>IIA.1.1 Task 1:</b> Secure Interest of Transplant Physicians	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• During this period we continued planning for a 2009 advanced training course for RITN centers to send staff to. The course is titled Advanced Radiation Medical Emergency training course and conducted in Oakridge, TN at the Radiation Emergency Assistance Center/Training Site (REAC/TS). Class will be held on March 26 &amp; 27, 2009. Course lessons include: <ul style="list-style-type: none"> <li>○ Basic Health Physics &amp; Radiation Protection: Part I</li> <li>○ A History of Serious Radiological Incidents: The Real Risk</li> <li>○ Health Physics &amp; Contamination Control: Part II</li> <li>○ Radiation Detection, Monitoring &amp; Protection Laboratory Exercise &amp; Quiz</li> <li>○ Diagnosis &amp; Management of the Acute Radiation Syndrome (ARS)</li> <li>○ Diagnosis &amp; Management of Internal Contamination</li> <li>○ Diagnosis &amp; Management of Acute Local Radiation Injury &amp; Case Review: Yanango Peru</li> <li>○ Radiation Sources &amp; Radiological Terrorism</li> <li>○ Radiation Emergency Area Protocol Demonstration</li> <li>○ Radiation Emergency Medical Management Drill</li> <li>○ Radiation Dose Estimations – Problem Solving Session</li> </ul> </li> <li>• During this period we initiated planning for the 2009 RITN conference “Nuclear Terrorism: Hematology/Oncology Center Preparedness” to be held in Bethesda, MD on May 18<sup>th</sup> (additional details of this conference are listed under AIM II A 2.1).</li> </ul>
<b>IIA.1.2 Task 2:</b> GCSF in Radiation Exposure	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>
<b>IIA.1 3 Task 3:</b> Patient Assessment Guidelines and System	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>

# **QUARTER PROGRESS REPORT**

## **Development of Medical Technology for Contingency Response to Marrow Toxic Agents**

**September 01, 2008 through December 31, 2008**

Enhancements	
<b>IIA 1.4 Task 4:</b> National Data Collection Model	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>
<b>IIA. Contingency Preparedness – Objective 2:</b> Coordination of the care of casualties who will require hematopoietic support will be essential in a contingency situation.	
<b>IIA.2.1 Task 1:</b> Contingency Response Network	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>Distributed FY09 RITN participation agreements to all 51 centers and formally invited six (6) additional transplant centers to participate in RITN, all have verbally agreed to participate and their signed participation agreements are under review by their legal teams: <ul style="list-style-type: none"> <li>Vanderbilt University in Nashville, TN</li> <li>CHORI in Oakland, CA</li> <li>Karmanos Cancer Center in Detroit, MI</li> <li>Mayo Clinic in Rochester, MN</li> <li>Mayo Clinic in Phoenix, AZ</li> <li>City of Hope in Phoenix, AZ</li> </ul> </li> <li>During this period we initiated planning for the 2009 RITN conference “Nuclear Terrorism: Hematology/Oncology Center Preparedness” to be held in Bethesda, MD on May 18, 2009. <ul style="list-style-type: none"> <li>We are planning for 200 attendees (a slight increase from the 2007 conference attendance)</li> <li>This conference will have a group session in the morning to provide a common operating picture then have three (3) interactive breakout workshops held three (3) times in the afternoon so that all attendees have the opportunity to participate.</li> <li>Morning sessions include: <ul style="list-style-type: none"> <li>Threat Scenario Overview</li> <li>National Disaster Medical System</li> <li>Medical response expectations 10, 100, 1,000 miles from epicenter</li> <li>Altered Standards of Medical Care Overview</li> </ul> </li> </ul> </li> </ul>

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****September 01, 2008 through December 31, 2008**

	<ul style="list-style-type: none"> <li>▪ NMDP Planning and data collection</li> <li>○ Afternoon interactive breakout workgroups include: <ul style="list-style-type: none"> <li>▪ Altered Standards of Care</li> <li>▪ Logistical issues – bed mgmt, use of non-hospital loc, &amp; staffing issues</li> <li>▪ Provision of medical care – early and late care</li> </ul> </li> <li>○ The conference will culminate with a report of findings by the afternoon session moderators, with the intent of publishing these findings later in the year.</li> </ul>
<b>IIA.2.2 Task 2:</b> Sibling Typing Standard Operating Procedures	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>
<b>IIA. Contingency Preparedness – Objective 3:</b> NMDP's critical information technology infrastructure must remain operational during contingency situations that directly affect the Coordinating Center.	
<b>IIA.3.1 Task 1:</b> I.S. Disaster Recovery	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>
<b>IIA.3.2 Task 2:</b> Critical Facility and Staff Related Functions	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• Business Continuity Planning: <ul style="list-style-type: none"> <li>○ Coordinated the installation of security film on all windows of the NMDP Repository to harden the face of the storage facility in the event of a natural or man made disaster that could compromise the building structure.</li> <li>○ Initiated the acquisition of donor center readiness kits to prepare these remote NMDP offices to better respond to incidents that impact their operations locally.</li> </ul> </li> </ul>



## QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

September 01, 2008 through December 31, 2008

**IIB. Rapid Identification of Matched Donors – Objective 1:** Increasing the resolution and quality of the HLA testing of volunteers on the registry will speed donor selection.

<b>IIB.1.1 Task 1:</b> Increase Registry Diversity	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>
<b>IIB.1.2 Task 2:</b> Evaluate HLA-DRB1 High Res typing	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>Closed</li> </ul>
<b>IIB.1.3 Task 3:</b> Evaluate HLA-C Typing of Donors	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>Closed</li> </ul>
<b>IIB.1.4 Task 4:</b> Evaluate Buccal Swabs	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>
<b>IIB 1.5 Task 5:</b> Enhancing HLA Data for Selected Donors	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>
<b>IIB 1.6 Task 6:</b> Maintain a Quality Control Program	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>

**IIB. Rapid Identification of Matched Donors – objective 2:** Primary DNA typing data can be used within the registry to improve the quality and resolution of volunteer donor HLA assignments.

<b>IIB 2.1 Task 1:</b> Collection of Primary Data	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>
--	--

## QUARTER PROGRESS REPORT

Development of Medical Technology for Contingency Response to Marrow Toxic Agents

September 01, 2008 through December 31, 2008

<b>IIB 2.2 Task 2:</b> Validation of Logic of Primary Data	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• Closed</li> </ul>
<b>IIB 2.3 Task 3:</b> Reinterpretation of Primary Data	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• Closed</li> </ul>
<b>IIB 2.4 Task 4:</b> Genotype Lists & Matching Algorithm	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>
<b>IIB. Rapid Identification of Matched Donors – Objective 3:</b> Registry data on HLA allele and haplotype frequencies and on the nuances of HLA typing can be used to design computer algorithms to predict the best matched donor.	
<b>IIB.3.1 Task 1:</b> Phase I of EM Haplotype Logic	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>
<b>IIB 3.2 Task 2:</b> Enhancement of EM Algorithm	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>
<b>IIB 3.3 Task 3:</b> Optimal Registry Size Analysis	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>
<b>IIB 3.4 Task 4:</b> Target Under- represented Phenotypes	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• No activity this period.</li> </ul>
<b>IIB 3.5 Task 5:</b> Bioinformatics Web Site	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• Closed</li> </ul>
<b>IIB 3.6 Task 6:</b> Consultants to Improve Algorithm	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>• Closed</li> </ul>

# **QUARTER PROGRESS REPORT**

## **Development of Medical Technology for Contingency Response to Marrow Toxic Agents**

**September 01, 2008 through December 31, 2008**

**IIB. Rapid Identification of Matched Donors – Objective 4:** Reducing the time and effort required to identify closely matched donors for patients in urgent need of HSC transplants will improve access to transplantation and patient survival in the context of a contingency response and routine patient care.

<b>IIB.4.1 Task 1:</b> Expand Network Communications	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>
<b>IIB.4.2 Task 2:</b> Central Contingency Management	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>
<b>IIB.4.3 Task 3:</b> Benchmarking Analysis	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>Closed</li> </ul>
<b>IIB.4.4 Task 4:</b> Expand Capabilities of Collection and Apheresis Centers	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>

**IIC. Immunogenetic Studies – Objective 1:** HLA mismatches may differ in their impact on transplant outcome, therefore, it is important to identify and quantify the influence of specific HLA mismatches. In contingency situations it will not be possible to delay transplant until a perfectly matched donor can be found.

<b>IIC.1.1 Task 1:</b> Donor Recipient Pair Project	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>
<b>IIC. Immunogenetic Studies – Objective 2:</b> Even when patient and donor are HLA matched, GVHD occurs so other loci may play a role.	
<b>IIC 2.1 Task 1:</b> Analysis of non-HLA loci	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>
<b>IIC 2.2 Task 2:</b> Related Pairs Research Repository	<b>Period 1 Activity:</b> <ul style="list-style-type: none"> <li>No activity this period.</li> </ul>

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****September 01, 2008 through December 31, 2008****IID. Clinical Research in Transplantation – Objective 1:** Clinical research in transplantation improves transplant outcomes and supports preparedness for a contingency response.

<b>IID.1.1 Task 1:</b> Observational Research, Clinical Trials and NIH Transplant Center	<b>Period 1 Activity:</b> <ul style="list-style-type: none"><li>• No activity this period.</li></ul>
<b>IID.1.2 Task 2:</b> Research with NMDP Donors	<b>Period 1 Activity:</b> <ul style="list-style-type: none"><li>• No activity this period.</li></ul>
<b>IID.1.3 Task 3:</b> Expand Immuno- biology Research	<b>Period 1 Activity:</b> <ul style="list-style-type: none"><li>• No activity this period.</li></ul>

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****September 01, 2008 through December 31, 2008****ACRONYM LIST**

AABB	American Association of Blood Banks	IDM	Infectious Disease Markers
AC	Apheresis Center	IHWG	International Histocompatibility Working Group
AHS	American Healthcare Solutions	IND	Investigational New Drug
AML	Acute Myelogenous Leukemia	IS	Information Services
ARS	Acute Radiation Syndrome (also known as Acute Radiation Sickness)	IT	Information Technology
ASBMT	American Society for Blood and Marrow Transplantation	IRB	Institutional Review Board
ASHI	American Society for Histocompatibility and Immunogenetics	KIR	Killer Immunoglobulin-like Receptor
B-LCLs	B-Lymphoblastoid Cell Lines	LN2	Liquid Nitrogen
BMT CTN	Blood and Marrow Transplant - Clinical Trials Network	LSSG	Life Science Strategy Group
BRT	Basic Radiation Training	NCI	National Cancer Institute
C&A	Certification and Accreditation	MHC	Major Histocompatibility Complex
CBMTG	Canadian Blood and Marrow Transplant Group	MICA	MHC Class I-Like Molecule, Chain A
CBB	Cord Blood Bank	MICB	MHC Class I-Like Molecule, Chain B
CBC	Congressional Black Caucus	MUD	Matched Unrelated Donor
CBS	Canadian Blood Service	NCBM	National Conference of Black Mayors
CBU	Cord Blood Unit	NIH	National Institutes of Health
CC	Collection Center	NIMS	National Incident Management System
CFU	Colony Forming Unit	NK	Natural Killer
CHTC	Certified Hematopoietic Transplant Coordinator	NMDP	National Marrow Donor Program
CIBMTR	Center for International Blood & Marrow Transplant Research	NRP	National Response Plan
CLIA	Clinical Laboratory Improvement Amendment	NST	Non-myeloablative Allogeneic Stem Cell Transplantation
CME	Continuing Medical Education	OCR/ICR	Optical Character Recognition/Intelligent Character Recognition
COG	Children's Oncology Group	OIT	Office of Information Technology

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****September 01, 2008 through December 31, 2008**

csDSR	Cancer Data Standards Repository	OMB	Office of Management and Budget
CREG	Cross Reactive Groups	ONR	Office of Naval Research
CT	Confirmatory Testing	PBMC	Peripheral Blood Mononuclear Cells
CTA	Clinical Trial Application	PBSC	Peripheral Blood Stem Cell
CWD	Common and Well Documented	PCR	Polymerase Chain Reaction
DC	Donor Center	PSA	Public Service Announcement
DIY	Do it yourself	QC	Quality control
DKMS	Deutsche Knochenmarkspenderdatei	RCC	Renal Cell Carcinoma
DMSO	Dimethylsulphoxide	RCI BMT	Resource for Clinical Investigations in Blood and Marrow Transplantation
DNA	Deoxyribonucleic Acid	REAC/TS	Radiation Emergency Assistance Center/Training Site
DR	Disaster Recovery	RFP	Request for Proposal
D/R	Donor/Recipient	RFQ	Request for Quotation
EBMT	European Group for Blood and Marrow Transplantation	RITN	Radiation Injury Treatment Network
EM	Expectation Maximization	RT	Room Temperature
EMDIS	European Marrow Donor Information System	SBT	Sequence Based Typing
FBI	Federal Bureau of Investigation	SCTOD	Stem Cell Therapeutics Outcome Database
FDA	Food and Drug Administration	SG	Sample Group
Fst	Fixation Index	SSA	Search Strategy Advice
GETS	Government Emergency Telecommunications Service	SSP	Sequence Specific Primers
GCSF	Granulocyte-Colony Stimulating Factor (also known as filgrastim)	SSOP	Sequence Specific Oligonucleotide Probes
GvHD	Graft vs Host Disease	STAR®	Search, Tracking and Registry
HHQ	Health History Questionnaire	TAT	Turn Around Time
HHS	Health and Human Services	TC	Transplant Center
HIPAA	Health Insurance Portability and Accountability Act	TED	Transplant Essential Data
HLA	Human Leukocyte Antigen	TNC	Total Nucleated Cell
HML	Histoimmunogenetics Mark-up Language	TSA	Transportation Security Agency

**QUARTER PROGRESS REPORT****Development of Medical Technology for Contingency Response to Marrow Toxic Agents****September 01, 2008 through December 31, 2008**

HR	High Resolution	URD	Unrelated Donor
HRSA	Health Resources and Services Administration	WGA	Whole-Genome Amplified
HSC	Hematopoietic Stem Cell	WMDA	World Marrow Donor Association
IBWC	Immunobiology Working Committee	WU	Work-up
ICRHER	International Consortium for Research on Health Effects of Radiation		